Bioprocess for the manufacturing of affordable pharmaceuticals to prevent and treat cancers, obesity and age-related diseases

“预计到2070年，65岁以上的人口将翻一番，增加与年龄有关的疾病的发病率，并将对医疗和社会护理基础设施造成额外的压力。长期的，具有成本效益的策略需要减少肥胖及其相关的共病的流行（和社会负担），并减少与年龄相关的疾病和癌症的发病率和对老年人口生活质量的影响。共轭亚油酸（CLA）是指ω-6不饱和脂肪酸，亚油酸的各种形式（异构体）的混合物。CLA的安全性和健康益处被记录在4000多份科学出版物中，并且已经发表了100多项人类研究。CLA是一种人体不能产生的必需营养素，在食物中含量不足，因此需要从膳食中补充。CLA是由亚油酸或富含亚油酸的油（向日葵和向日葵）作为四种异构体的混合物进行化学转化而生产的，这些异构体不能以成本效益的方式分离。不同的异构体可表现出相加的、独立的或拮抗的生理作用。纯的异构体无法在市场上买到;因此，大多数对人类和动物的研究都是使用异构体混合物进行的，这模糊了结果，并阻碍了对单个异构体发挥其健康作用的机制的阐明。其中一种CLA异构体具有有效的抗肥胖、抗癌、抗骨质疏松和抗动脉粥样硬化活性，同时改善能量平衡和保持瘦肌肉。然而，在其他异构体的存在下，其有益效果降低，这些异构体也可能具有不期望的效果。因此，在医疗上，迫切需要这种纯的异构体作为一种低成本的预防和治疗多种代谢紊乱的药物。本项目将研究一种新的路线来生产这些纯的CLA异构体，作为第一步，为癌症、肥胖症和年龄相关疾病提供具有成本效益的治疗方法。总部位于英国的SMME公司VideraBio和英国合成生物学中心SynBio将合作提供这一尖端创新。"

"The population over the age of 65 is predicted to double by 2070, increasing the incidence of age-related diseases and will put additional pressure on the medical and societal care infrastructure. Long term, cost-effective strategies are required to decrease the prevalence (and societal burden) of obesity and its associated co-morbidities, and to reduce the incidence and impact of age-related disorders and cancer on the quality of life of an ageing population.Conjugated linoleic acid (CLA) refers to a mixture of various forms (isomers) of the omega-6 unsaturated fatty acid, linoleic acid. The safety and health benefits of CLA are documented in \>4000 scientific publications, and \>100 human studies have been published. It is an essential nutrient not produced by the body and not present in sufficient amounts in food, thus requiring dietary supplementation.CLA is commercially produced by chemical conversion of linoleic acid or oils rich in linoleic acid (sunflower and saffron) as a mixture of four isomers that cannot be separated cost-effectively. The different isomers may exhibit additive, independent or antagonistic physiological effects. Pure isomers are not commercially available; thus, most studies on humans and animals were performed with isomer mixtures, which obscured the results and hinders elucidation of the mechanisms through which the individual isomers exert their health effects.One of these CLA isomers has potent anti-obesity, anti-cancer, anti-osteoporosis and anti-atherosclerosis activity, while improving energy balance and maintaining lean muscle. However, its beneficial effects are reduced in the presence of the other isomers which may also have undesirable effects. Thus, for medical purposes, this desired isomer in pure form is urgently required as a low-cost preventative and curative treatment for a wide variety of metabolic disorders.This project will investigate a novel route to produce these CLA isomers in pure form as a first step to provide cost-effective treatments for cancer, obesity and age-related disorders. VideraBio, a UK-based SMME, and BrisSynBio (a UK Synthetic Biology Centre) will collaborate to deliver this cutting-edge innovation."